Latest News

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.
MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

January 10th 2025

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes
CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes

January 1st 2025

New Developments in CAR T Treatments Webinar Series Summary
New Developments in CAR T Treatments Webinar Series Summary

December 24th 2024

3 Things You Should Know About Hemolytic Anemias
3 Things You Should Know About Hemolytic Anemias

December 20th 2024

NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia
NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia

December 19th 2024